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A
utosomal recessive juvenile parkinsonism (ARJP) is an early
onset familial form of Parkinson’s disease. The distinguish-
ing features of ARJP from the more prevalent idiopathic form of
the disease include its earlier onset age, slower disease course,
occasional dystonia, and long-lasting response to low doses of L-
dopa. ARJP is thought to result from mutations in one or more
genes, including the gene that encodes the E3 ubiquitin ligase
parkin,
1 accounting for approximately 50% of allcases.Parkin, as
with all E3 ligases, is an important enzyme in the ubiquitin-
mediated proteolysis pathway. It has been shown to covalently
link ubiquitin to potential substrates such as Eps15,
2,3 CDCrel-
1,
4 R-synuclein,
5 synphilin-1,
6 AIMP2,
7 and FBP-1.
8 However,
conﬁrmation of some of these substrates and their functional
outcomes remains controversial.
9,10 More recently, parkin has
beenshowntohaveanimportantroleinmitochondrialfunction.
Parkin ubiquitination of mitochondrial proteins serves to recruit
and assemble the autophagy machinery to clear impaired
mitochondria.
11 Interestingly, the activity of complex I of the
mitochondrial respiratory chain is decreased in the substantia
nigra and other tissues in Parkinson’s disease patients. Further,
several complex I inhibitors reproduce key features of Parkin-
son’s disease such as loss of dopaminergic neurons and motor
deﬁcits.
12,13
Parkin is a multidomain E3 ubiquitin ligase consisting of 465
amino acids with ﬁve distinct domains: an N-terminal ubiquitin-
like (Ubl) domain followed by a unique parkin-speciﬁc domain
(UPD), a RING0 domain, and two C-terminal RING domains
separatedbyanin-betweenRING(IBR)domain.
14TheN-term-
inal Ubl domain has been shown to be essential for the ligase
activity of parkin since deletion or mutation of this domain
resultsinimpairedE3ligaseactivity.
5,15TheUbldomainhasalso
beenshowntoparticipateinavarietyofproteininteractions.For
example, binding of the Ubl domain to the S5a proteasomal
subunit has been suggested to position parkin and its bound
substrates near the degradation machinery.
16 Alternatively, the
parkin Ubl domain has been shown to interact with the en-
docytotic protein, Eps15
2,3,16, in order to facilitate Eps15 ubiqui-
tination used in the Akt signaling cascade.
Early onset PD has been linked to homozygous and com-
pound heterozygous mutations in the parkin gene. However,
heterozygous mutations in parkin also exist and are more
controversial
17 including some that are likely polymorphisms.
Approximately 95 nonstop, missense mutations are associated
with ARJP (see http://www.molgen.ua.ac.be/PDmutDB and
http://www.hgmd.org) and are located throughout the parkin
generesultinginsingleresiduesubstitutionsinthecodedprotein
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ABSTRACT: Autosomal recessive juvenile parkinsonism
(ARJP) is an early onset familial form of Parkinson’s disease.
Approximately 50% of all ARJP cases are attributed to muta-
tionsinthegenepark2,codingfortheproteinparkin.Parkinisa
multidomain E3 ubiquitin ligase with six distinct domains
including an N-terminal ubiquitin-like (Ubl) domain. In this
work we examined the structure, stability, and interactions of
the parkin Ubl domain containing most ARJP causative muta-
tions. Using NMR spectroscopy we show that the Ubl domain
proteins containing the ARJP substitutions G12R, D18N,
K32T, R33Q, P37L, and K48A retained a similar three-dimen-
sional fold as the Ubl domain, while at least one other (V15M) had altered packing. Four substitutions (A31D, R42P, A46P, and
V56E)resultinpoorfoldingofthedomain,whileoneprotein(T55I)showedevidenceofheterogeneityandaggregation.Further,of
thesubstitutions thatmaintainedtheirthree-dimensionalfold,wefoundthatfourofthese (V15M, K32T,R33Q,andP37L)leadto
impaired function due to decreased ability to interact with the 19S regulatory subunit S5a. Three substitutions (G12R, D18N, and
Q34R) with an uncertain role in the disease did not alter the three-dimensional fold or S5a interaction. This work provides the ﬁrst
extensive characterization of the structural eﬀects of causative mutations within the ubiquitin-like domain in ARJP.2604 dx.doi.org/10.1021/bi200065g |Biochemistry 2011, 50, 2603–2610
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(for a summary see refs 18 and 19). This includes at least 20
substitutions at 16 diﬀerent positions in the Ubl domain. Some
disease state mutations localized to the Ubl domain have been
shown to decrease the stability of the full-length parkin protein
in vivo, although conﬂicting evidence has been presented for the
eﬀectsofthemutationsonE3ligaseactivity.
15,20,21Todate,ithas
been diﬃcult to distinguish whether the observations arise from
substitutions causingstructuralorfolding alterationsinparkin or
are a result of disrupted protein interactions with E2 ubiquitin
conjugating enzymes, potential substrates, or the S5a proteaso-
mal subunit. One reason for this uncertainty has been the
inability to purify parkin, its constitutive domains, and especially
proteins containing disease-causing mutations on a large scale
suitable for biophysical studies. To date, only the parkin Ubl
16,22
and IBR
23 domains have been puriﬁed and their three-dimen-
sional structures determined. While some mutant forms of the
parkin IBR domain have been isolated and characterized,
23
similar approaches have not been completed for the Ubl domain
mutant containing proteins. To date, only two substitutions
(K48A, R42P) have been structurally examined in the Ubl
domain leaving the majority of the disease-related substitutions
uncharacterized.
3,24 Further, while a large number of mutations
in the RING domains have been examined for interactions with
diﬀerent E2 enzymes
25 and ubiquitination,
20,25-27 similar
comprehensive studies have not been completed for the Ubl
domain.
In this work we have examined proteins carrying ARJP
disease-associated mutations at 13 of the possible 16 positions
in the parkin Ubl domain in order to identify the impact of these
substitutions on the Ubl domain structure, stability, and interac-
tions with the S5a proteasome. Our work provides evidence that
several ARJP disease state mutations cause drastic alterations in
the Ubl domain structure and/or stability, while others disrupt
binding to the S5a proteasomal subunit. These observations
provide two diﬀerent mechanisms that ARJP-associated mis-
sense mutations in the parkin gene may contribute to the
dysfunction of the protein in the ubiquitination pathway.
’EXPERIMENTAL PROCEDURES
Cloning. The DNA fragment encoding the Ubl domain
(residues 1-77) of human parkin was cloned into the NdeI
and BamHI sites of the pET44a vector (Novagen). The sub-
stitutions G12R, V15M, D18N, A31D, K32T, R33Q, Q34R,
P37L, R42P, A46P, K48A, T55I, and V56E in the Ubl domain
werecreatedusingtheQuikChangesite-directedmutagenesiskit
(Stratagene, La Jolla, CA). The DNA fragment encoding the
UIMs (residues 196-309) of the human proteasomal S5a
subunit was cloned into a pET21a vector (Novagen) modified
to include a tobacco etch virus protease cleavage site before the
six-residue histidine C-terminal tag. For expression with an in-
frame N-terminal GB1 fusion, the DNA fragment encoding the
Ubl domain (1-77) was cloned into the NheI and XhoI sites of
the GEV1 vector,
28 a generous gift from Dr. M. Clore (NIDDK,
Bethesda, MD). The V56E substituted version of the GB1-Ubl
domain fusion was created using the QuikChange site-directed
mutagenesis kit.
ProteinExpressionandPurification.TheUbldomain,GB1-
Ubl domain, and all substituted proteins were overexpressed in
the BL21(DE3) Codon PlusRIL Escherichia coli strain and
purified as previously described using the same chromatographic
methods.
24 The S5a
196-309 fragment containing both UIM
regionswasexpressedwithasix-residuehistidinetagandpurified
using a Ni-NTA FPLC affinity column (GE Healthcare) fol-
lowed by size exclusion chromatography. Ubiquitin from Sac-
charomyces cerevisiae was expressed from a pET3a vector as
previously described.
29 The integrity of all proteins was con-
firmed by electrospray ionization mass spectrometry (UWO
Biological Mass Spectrometry Laboratory).
NMR Spectroscopy. All NMR experiments were performed
on a 600 MHz Varian Inovaspectrometerequippedwitheithera
13C-enhanced triple resonance cold probe with z-gradients or an
xyz gradient, triple resonance probe (Biomolecular NMR Facil-
ity, UWO).
1H chemical shifts were referenced directly to
internal DSS at 0 ppm. Sensitivity-enhanced
1H-
15N HSQC
spectra
30 were recorded at 25 Co n
15N-labeled proteins in
10 mM KH2PO4, 1 mM EDTA, 1 mM DTT, 30 μM DSS, and
10%D2OatpH7.0.AllspectrawereprocessedwithNMRPipe
31
software using a 60 shifted, cosine-squared function in both
1H
and
15N dimensions and analyzed using NMRView.
32
Protein Unfolding Experiments. Unfolding experiments
were monitored by circular dichroism (CD) spectropolarimetry
using a Jasco J-810 instrument (Biomolecular Interactions and
Conformations Facility, UWO). Spectra (190-250 nm) were
initially measured at 5 C using ten averaged scans for protein
samples ranging in concentration from 20 to 80 μMi na1m m
cell. Following this, the ellipticity at 222 nm was measured as a
function of temperature between 5 and 95 C using a 1 C/min
temperature gradient. Data were analyzed by plotting the ob-
served ellipticity as a function of temperature and fitting for the
meltingpointtransition(Tm)andtheenthalpy(ΔHm)according
to eq 1. During the fitting process a heat capacity (ΔCp) of 3.1
kJ/(molK) wasusedbased on calculated accessible surface areas
ofthefoldedandunfoldedUbldomain.
33,34Thedatawerefound
tobeinsensitivetoheatcapacityasfitsdoneusingΔCp0kJ/(mol
K) yielded near identical values for Tm and ΔHm.
ΔG ¼ ΔHm 1-
T
Tm

þ ΔCp ðT - TmÞ - T ln
T
Tm
 
ð1Þ
The diﬀerences in stability (ΔΔG) between substituted Ubl
domain proteins and the wild-type protein were calculated using
ΔHm(wt), Tm(wt), and the diﬀerences in melting temperatures
(ΔTm) between the wild type and the appropriate substituted
proteins
35 according to eq 2.
ΔΔG ¼ ΔTm
ΔHmðwtÞ
TmðwtÞ
ð2Þ
Ubl Domain-S5a Binding Assays. Purified His-tagged
S5a
196-309 was mixed with untagged Ubl domain, substituted
Ubl domain proteins, or ubiquitin at a 1:2 molar ratio, respec-
tively,inatotalvolumeof300μLandplacedonarotatingshaker
at4Cfor1h.ThemixturewasthenloadedontoaNi-NTAspin
column (Qiagen) preequilibrated in binding buffer (20 mM
sodiumphosphate,10mMimidazole,300mMNaCl,pH8).The
columnwaswashedtwicewith600μLofbindingbufferandthen
eluted (20 mM sodium phosphate, 250 mM imidazole, 300 mM
NaCl, pH 8). Elution samples were fractionated by electrophor-
esisonatricine-polyacrylamidegelandstainedwithCoomassie
brilliant blue dye. Protein concentrations were determined using
the extinction coefficient method measured in guanidine hydro-
chloride.
362605 dx.doi.org/10.1021/bi200065g |Biochemistry 2011, 50, 2603–2610
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’RESULTS
The three-dimensional structure of the parkin Ubl domain
comprises a β-grasp fold (Figure 1) containing a ﬁve-strand
β-sheet (β1, H11-V15; β2, I2-F7; β3, R42-F45; β4, K48-
L50; and β5, Q64-V70) and two R-helices (R1, S22-Q34;
R2, V56-D60).
16 This structure is characteristic of other ubiqui-
tin-like domains such as hPLIC-2 and hHR23a
37,38 and
ubiquitin.
39 Despite these structural similarities, the parkin Ubl
domain is nearly 11 kJ/mol less stable than ubiquitin.
24 The
lower stability of the parkin Ubl domain may be an inherent
property of the domain or might indicate that intramolecular
interactions with other domains in the protein are needed to
enhance its stability. Therefore, missense mutations in the Ubl
domain could contribute to its improper folding, instability that
would interfere with the overall structure of parkin or compro-
miseitsinteractionswithotherproteins.Todeterminetheeﬀects
ofARJPmutationsonthestructureandstabilityoftheparkinUbl
domain, we used site-directed mutagenesis to create 13 of the
possible substituted proteins. NMR spectroscopy was used to
assess how each of these single residue substitutions might aﬀect
the overall structure of the proteins. Thermal denaturation, as
measured by CD spectropolarimetry, was used to identify the
change in stability caused by the substitutions. Both of these
methods were used to determine whether structural alterations
might render the Ubl domain ineﬀective for interaction with the
proteasomal S5a subunit. The substitutions investigated covered
most secondary structure regions of the Ubl domain including
G12R (Ubld
G12R) and V15 M (Ubld
V15M)i nβ1; R42P
(Ubld
R42P)i nβ3; K48A (Ubld
K48A)i nβ4; A31D (Ubld
A31D),
K32T (Ubld
K32T), R33Q (Ubld
R33Q), and Q34R (Ubld
Q34R)i n
β1; V56E (Ubld
V56E)i nβ2; and D18N (Ubld
D18N), P37L
(Ubld
P37L), A46P (Ubld
A46P), and T55I (Ubld
T55I) in loop
regions (Figure 1). The ARJP substitution Ubld
R42P 40 and
another reported,
41 but not conﬁrmed (Ubld
K48A), have been
previously described
24 and are included here for completeness.
The proteins covered 13 of the 16 sites for ARJP mutations. The
only substitutions not assessed were at the initiating methionine
position (M1L) and S10N and W54R that were reported after
this work was started.
Most Ubl domain substituted proteins with the exception of
Ubld
A31D, Ubld
R42P, Ubld
A46P, and Ubld
V56E expressed well and
producedyieldscomparabletothatofthewild-typeprotein. The
Ubld
A31D protein expressed at very low levels, could not be
puriﬁed to homogeneity, and was not further investigated in
these studies. The Ubld
A46P and Ubld
V56E proteins were ex-
pressed, but more than 90% of the protein was found in the
insoluble fraction of the cell lysate as determined from Coomas-
sie stained gels (data not shown). Attempts to purify these
proteins showed wide variations in heterogeneity and suscept-
ibility to proteolysis as determined by mass spectrometry. The
Ubld
T55I protein was expressed and could be puriﬁed intact, but
preliminaryNMRspectrashowedaheterogeneouspopulationof
peaks with diﬀerent line widths. The behaviors of Ubld
A31D,
Ubld
A46P, Ubld
T55I, and Ubld
V56E are consistent with poorly
foldedproteinstructuresthataresensitivetodegradationand/or
aggregation, similar to that observed for Ubld
R42P. To circum-
vent this issue, we selected a candidate protein (Ubld
V56E)t o
express as a fusion protein linked to the B1 domain from imm-
unoglobulin G (GB1), similar to that described previously for
Ubld
R42P.
24 The resulting protein GB1-Ubld
V56E could be
expressed to high levels and puriﬁed to homogeneity for struc-
tural characterization.
Parkin R42P, A46P, and V56E Substitutions Cause Ubl
Domain Unfolding. CD spectropolarimetry and NMR spec-
troscopywereusedtodeterminewhetheranysignificantchanges
to the secondary and tertiary structures of the substituted
proteins occurred compared to the wild-type Ubl domain. The
CD spectrum of the wild-type Ubl domain at 5 C had well-
defined minima near 208 and 225 nm (Figure 2) consistent with
its three-dimensional structure, which contains approximately
21% R-helix and 43% β-sheet. A comparison of the CD spectra
for Ubld
P37L (Figure 2) and several other substituted proteins
(Ubld
G12R,U b l d
V15M,U b l d
D18N,U b l d
K32T,U b l d
R33Q,U b l d
Q34R,
Ubld
K48A) with the wild-type Ubl domain showed less than 5%
difference between the spectra, indicating that the secondary
structure of these Ubl domain proteins was very similar to the
normal protein at this temperature. A CD spectrum of Ubld
A46P
Figure 1. Ribbon drawing of the parkin Ubl domain illustrating the
location of ARJP disease state substitutions. Side chains are indicated in
red and labeled with the ARJP causative substitution. This ﬁgure was
produced using the program PyMOL
48 using the human parkin Ubl
domain structure (Protein Data Bank 1IYF).
16
Figure 2. Folding comparison of substituted Ubl domains using
CD spectropolarimetry. The spectrum of the wild-type parkin Ubl
domain is shown (-) compared to the Ubld
P37L protein (---) that
maintained a similar fold. The spectrum of the Ubld
A46P protein (333)
which had little secondary structure and was shown by mass spectro-
metry to be sensitive to proteolysis is also shown. All spectra were
collected using 20-80 μM protein in 10 mM KH2PO4, 1 mM EDTA,
and 1 mM DTT, pH 7.0 at 5 C.2606 dx.doi.org/10.1021/bi200065g |Biochemistry 2011, 50, 2603–2610
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(Figure 2) showed very poor signal from R-helix or β-sheet
structure indicating this protein was likely unfolded. Analysis of
thissampleusingmassspectrometrysubsequenttoCDmeasure-
ment revealed that a portion of the protein had undergone
proteolysis.
Each of the Ubl domain substituted proteins was examined by
comparing their
1H-
15N HSQC spectrum with the wild-type
parkin Ubl domain spectrum (Figure 3). It was expected that a
benign single site substitution should have only local eﬀects on
the spectrum reﬂecting the amino acid change whereas a greater
disruption in structure would be reﬂected in a large number of
spectral changes, especially for residues remote from the sub-
stitution. The
1H-
15N HSQC spectra for the Ubld
G12R,
Ubld
V15M, Ubld
D18N,U b l d
K32T, Ubld
R33Q, Ubld
Q34R,U b l d
P37L,
and Ubld
K48A proteins (Figure 3 and Figure S1 of Supporting
Information) all had well-dispersed peaks and similar spectral
patterns to the wild-type Ubl domain spectrum. In several cases
(Ubld
D18N, Ubld
K32T,U b l d
R33Q, Ubld
P37L, and Ubld
K48A) the
single amino acid substitutions resulted in minimal changes in
the NMR spectrum. For example, in the Ubld
K32T protein
(Figure 3A) the appearance of a new peak for T32 and a large
shift of the neighboring R33 occurred while the remainder of the
spectrum was unaﬀected. This is consistent with a minor
environmental change around position 32 with little alteration
instructure.Incontrast,the
1H-
15NHSQCspectrumforUbld
V15M
resulted in changes in chemical shift to the adjacent residues E16,
V17, and D18 but also to V29 and V30 in the R1 helix and several
residues (F4, V5, F7) in β2. In the Ubl domain structure, V15 packs
against V29 and V30 and has backbone contacts with M1-V3 near
the N-terminus, indicating the V15M substitution likely aﬀected the
packing between these residues. A similar observation was noted for
the Q34R substitution.
Since the Ubld
V56E protein could not be puriﬁed in suﬃcient
levels and was susceptible to proteolysis, the protein was linked
to the B1 domain from immunoglobulin G (GB1; GB1-Ubld
V56E)
to improve these properties. The resulting
1H-
15NH S Q Cs p e c -
trum (Figure 4) displayed a population of well-dispersed peaks that
were in excellent agreement with those observed in the
1H-
15N
HSQC spectrum of the isolated GB1 domain.
28 This indicated that
the GB1 domain maintained its native fold having little interaction
with the Ubld
V56E portion of the construct. The remaining peaks
Figure3.
1H-
15NHSQCspectraofparkinUbldomainandsubstitutedproteinsresultingfromARJPmutations.Superpositionofspectrafortheparkin
Ubl domain (black) with (A) Ubld
K32T (red) and (B) Ubld
V15M (red). In each panel selected residue assignments are shown that have the largest
chemical shift diﬀerences from the wild-type Ubl domain. Anarrow isused to indicate the positions ofpeaks for the substituted residue in the wild-type
and substituted proteins.
Figure 4.
1H-
15N HSQC spectra of GB1-Ubld
V56E showing the
unfolded nature of Ubld
V56E. The spectrum of the GB1-Ubld
V56E
protein is plotted in black contours while the isolated GB1 protein is
shown in red contours. The spectra were collected at 600 MHz in
10 mM KH2PO4, 1 mM EDTA, and 1 mM DTT, pH 7.0 at 25 C.2607 dx.doi.org/10.1021/bi200065g |Biochemistry 2011, 50, 2603–2610
Biochemistry ARTICLE
arising from the Ubld
V56E protein had little resemblance to the
1H-
15N HSQC spectrum of the wild-type Ubl domain or most of
thesubstitutedproteins(Figure3).Thenondispersenatureofthese
peaks and their tight clustering between 8.0 and 8.5 ppm in the
1H
dimension indicated the Ubld
V56E protein was unfolded. Subse-
quent to the NMR experiments, size exclusion chromatography
showed the elution volume of GB1-Ubld
V56E was much smaller
than expected for a 16 kDa protein, consistent with its unfolded
structure. A similar observation has been made previously for
Ubld
R42P.
24 Overall, these results indicate that the Ubl domain
proteins containing the ARJP mutations G12R, D18N, K32T,
R33Q, P37L, and K48A retain a similar three-dimensional fold as
the wild-type domain, while at least two others (Ubld
V15M,
Ubld
Q34R) have evidence of altered packing. In contrast, three
substitutions (R42P, A46P, and V56E) result in gross structural
diﬀerences due to unfolding of the domain.
FoldedARJPSubstitutedProteinsLeadtoDifferentialUbl
Domain Stability. The substituted proteins (Ubld
G12R,
Ubld
V15M, Ubld
D18N,U b l d
K32T, Ubld
R33Q, Ubld
Q34R,U b l d
P37L,
Ubld
K48A) that exhibited a folded structure were examined to
determine if the substitutions had altered the stabilities of the
proteins. This was done using thermal unfolding of each protein
andmonitoringthechangeinellipticityat222nmasafunctionof
temperature. Initial spectra were recorded at 5 C where the CD
spectra of the selected substituted proteins were similar to the
wild-type protein (Figure 2). Most of the melting curves for
native parkin Ubl domain and the ARJP substituted proteins
showed smooth sigmoidal transitions between folded and un-
folded species indicative of a two-state unfolding process
(Figure 5). Ubld
D18N and Ubld
K32T had shallower slopes that
mightindicatesomedeviationfromthismodel.Thedatawerefit
using eq 1 to determine the midpoint of the transition (Tm) and
the enthalpy (ΔHm). The data showed that the parkin Ubl
domain had a melting temperature (Tm) near 63 C (Table 1).
There were three ARJP-substituted proteins that melted at
higher temperatures (Ubld
G12R, Ubld
D18N, Ubld
P37L) and five
substituted Ubl domain proteins that unfolded at lower tem-
peratures including Ubld
R33Q and Ubld
K48A that melted nearly
10 C lower than the wild-type protein. The difference in
stabilities was calculated using the method of Becktel and
Schellman using the ΔHm for the wild type and the Tm for each
protein.
35 These results generally followed the order of the
melting stabilities indicating that Ubld
D18N was the most stable
protein and Ubld
K48A had the poorest stability.
ARJP-Substituted Proteins Compromise S5a Interaction.
TheinteractionoftheparkinUbldomainwiththe19Sregulatory
subunit S5a was studied using residues 196-309 of the 377
amino acid protein. This fragment (S5a
196-309) could be ex-
pressedandpurifiedwithasix-residuehistidinetagandpossesses
ubiquitininteractingmotifs(UIMs)shownpreviouslytointeract
with the parkin Ubl domain.
16 To assess the impact of different
ARJP substitutions on the interaction of the Ubl domain with
S5a
196-309, affinity pull-down experiments were employed. Figure 6
shows that His-tagged S5a
196-309 bound to Ni-NTA beads
successfully pulled down untagged parkin Ubl domain. The
S5a fragment also bound similarly to Ubld
G12R, Ubld
D18N, and
Ubld
Q34R, indicating these substitutions are not involved at the
parkin Ubl domain-S5a interface. However, S5a
196-309 inter-
actions with the parkin- substituted proteins Ubld
V15M,U b l d
K32T,
Ubld
R33Q,a n dU b l d
P37L were notably weaker than wild-type Ubl
domain, similar to previous observations with the Ubld
K48A
protein.
3 Since NMR experiments show some of these proteins
(Ubld
K32T,U b l d
R33Q, and Ubld
P37L) retain a similar three-
dimensional fold as the parkin Ubl domain, this indicates the
substitutions likely interfere with formation of a proper parkin
Figure 5. Thermal unfolding curves for the parkin Ubl domain and substituted proteins resulting from ARJP disease state mutations. Data were
collected using CD spectropolarimetry between 5 and 95 C using a 1 C/min temperature gradient. The ellipticity at 222 nm was plotted as fraction
unfolded and ﬁt according to equations described in Experimental Procedures. All samples were comprised of 20-80 μM protein in 10 mM KH2PO4,
1 mM EDTA, and 1 mM DTT, pH 7.0.
Table 1. Thermodynamic Parameters for Substituted Parkin
Ubl Proteins
protein Tm (C)
a ΔHm (kJ/mol)
b ΔΔG (kJ/mol)
c
parkin Ubl domain 62.7(0.1 246.8( 9.5
G12R 64.0 (0.1 271.2(16.2 -1.0
V15M 60.2(0.1 246.2(7.9 1.8
D18N 68.7(0.1 336.7(14.9 -4.4
K32T 61.9( 0.2 117.1(7.6 0.6
R33Q 54.1(0.1 198.9( 8.5 6.3
Q34R 58.4(0.1 267.3(8.0 3.2
P37L 68.0(0.1 223.5(7.1 -3.9
K48A 53.2(0.2 179.2(8.4 7.0
aDetermined from nonlinear ﬁt using ΔCp = 3.1 kJ mol
-1 K
-1
according to eq 1.
bCalculated from the linear ﬁt near the Tm of ln K
= ΔS/R -ΔH/R(1/T).
cEstimated usingeq 2 and Tm, ΔHm for parkin
Ubl domain wild-type protein.2608 dx.doi.org/10.1021/bi200065g |Biochemistry 2011, 50, 2603–2610
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Ubl domain-S5a interface. As expected, little or no interaction
between S5a
196-309 and ubiquitin was observed.
’DISCUSSION
Of the 13 substituted proteins we examined, ﬁve of them
(Ubld
A31D, Ubld
R42P, Ubld
A46P, Ubld
T55I, and Ubld
V56E)
showed signiﬁcant structural alterations. For the Ubld
A31D
protein, its low level of expression in bacteria compared to wild
type is evidence for a poorly folded protein with decreased
stability that may be subject to proteolysis. Similarly, Ubld
A46P
showed little secondary or tertiary structure and was easily
degraded. The Ubld
T55I protein showed evidence of heteroge-
neity and aggregation in NMR spectra. In previous studies we
used an N-terminal GB1 tag to stabilize and protect the Ubl
domainproteins from degradation.BothUbld
V56Eand Ubld
R42P
had
1H-
15NHSQCspectraconsistentwithanunfoldedstatefor
theUbldomainportionoftheprotein.IntheparkinUbldomain,
V56 is 95% buried near the N-terminus of the short R2 helix and
participates in hydrophobic interactions with the side chains of
M1,V17,andL61.Moleculardynamicsexperimentssuggestthat
substitution of this hydrophobic residue with a charged glutamic
acid residue would disrupt these interactions.
42 Similarly, A46 is
located in the loop region between β3 and β4, and the substitu-
tion of alanine to proline would disrupt its hydrogen bonding to
I66 in β5. Further, the addition of proline at this position could
restrict the ﬂexibility of the loop. As shown previously for
Ubld
R42P, disruption of hydrogen bonding within the β-sheet
regions can lead to unfolding of the entire domain.
24
The eight proteins that contained substitutions but formed
folded domains showed diﬀerential interactions with the tandem
UIM region from the S5a subunit, proposed toallow foreﬃcient
delivery of polyubiquitinated cargo to the proteasome for
degradation. The Ubld
K48A substitution resulted in decreased
binding with S5a consistent with previous results showing this
residue is involved in the interaction with the UIM region(s)
from either S5a or Eps15.
3 In contrast, the Ubld
V15M, Ubld
K32T,
Ubld
R33Q, and Ubld
P37L proteins showed diminished binding
compared to wild-type Ubl domain even though none of these
residuesliesonthebindinginterfacerequiredforS5ainteraction.
Three ofthesubstitutions (Ubld
V15M,Ubld
K32T, Ubld
R33Q)lead
to decreased stability of the Ubl domain. It is noted that V15,
K32, and R33 all interact with F13 in sheet β1, a residue aﬀected
by S5a binding. The decreased stability of the Ubl domain
carrying these substitutions suggests that some modiﬁcation of
the S5a binding site has occurred. It is not clear why decreased
S5a binding to the Ubld
P37L protein occurs as this substitution
leads to increased domain stability. The similarity of S5a binding
to Ubld
G12R and Ubld
D18N compared to wild-type Ubl domain
was in agreement with their maintenance of three-dimensional
fold and similar or increased stabilities. Although G12 is aﬀected
by the interaction with the UIMs from Eps15, neither substitu-
tion is at the interaction surface for S5a.
3
ThedownstreameﬀectsofsomeinteractionsoftheparkinUbl
domain have been validated in vitro and in vivo. It was recently
shown that the interaction of the parkin Ubl domain with the
regulatory particle of the proteasome activates the 26S
proteasome.
43 This interaction provides a direct link between
the cellular ubiquitination machinery and the regulation of the
degradation machinery in the cell. The upregulation of protea-
some activity was also shown in Drosophila where a K71P
substitution(correspondingtoR42Phere)showednoregulation
of proteasome activity, further indicating that a correctly folded
Ubl domain is essential to the function of parkin in vivo.
Several ARJP substitutions in the Ubl domain shown to
cause unfolding (Ubld
R42P,U b l d
V56E)o rl a r g ed e c r e a s e si n
stability (Ubld
R33Q,U b l d
K48A) alter the behavior of the full-
length protein in vivo. In work done by Henn et al.
15 ARJP
substitutions including R33Q, R42P, K48A, and V56E re-
sulted in decreased stability of the full-length protein in N2a
cells. This eﬀect was shown to be a result of an increased
degradation of parkin by the 26S proteasome. Another inter-
action where substitutions in the Ubl domain have been
shown to aﬀect its function is in the parkin interaction with
the SH3 domain of endophilin-A1.
44 It was observed that in
vitro parkin ubiquitinated endophilin-A1. The Ubl domain
with the reported ARJP causative substitutions R42P and
K48A was shown to disrupt this interaction, providing a new
linkbetweenmutationsinparkinanddisruptiontoproteinsin
synaptic transmission.
These results clearly demonstrate there are multiple out-
comes of the diﬀerent ARJP disease-state mutations in the
parkin Ubl domain. Some of these substitutions (A31D, R42P,
A46P, T55I, V56E) result in disruption of the domain fold.
Others, while maintaining the three-dimensional fold of the Ubl
domain, have defects in interactions with the S5a subunit
including K48A that has not been clearly linked to ARJP.
Further, one must consider the outcomes of three of the
substitutions (G12R, D18N, Q34R) that have little eﬀect on
the three-dimensional fold or S5a interaction. The correspond-
ing mutations in the parkin gene are observed in the hetero-
zygous state
17,45-47 and could simply be a result of a poly-
morphism that has little impact on the protein function. Alter-
natively, it is possible that some of the disease-state residues in
the parkin Ubl domain could be stabilized or are important for
other essential, unidentiﬁed interactions with the remaining
portions of the protein. Further studies will be needed to clarify
the roles of these residues in parkin function and in ARJP.
Figure 6. ARJP substitutions in the Ubl domain disrupt S5a interac-
tions. His6-S5a
196-309 was incubated with 2 molar equiv of the parkin
Ubl domain, substituted protein, or ubiquitin for 1 h and then loaded
onto a Ni-NTA spin column. Following elution the samples were
fractionated on a 16.5% tricine gel and stained with Coomassie dye.
The top panel shows the bound proteins eluted with His6-S5a
196-309 as
follows: Ubld
G12R (lane 1), Ubld
V15M (lane 2), Ubld
D18N (lane 3),
Ubld
R33Q (lane 4), Ubld
Q34R (lane 5), Ubld
P37L (lane 6), Ubld
K48A
(lane 7), Ubl domain (lane 8), ubiquitin (lane 9), and His6-S5a
196-309
alone(lane13).LowerquantitiesofUbld
K32T(lane11)wereusedinthe
assay (although at the same molar ratio as the other mutants) so parkin
Ubldomainwasassayedagainatthisconcentration(lane12).Molecular
weightmarkersareshowninlane10.Thelowerpanelillustratesthepure
proteins as used in the pull-down assay and correspond to the same
labels.2609 dx.doi.org/10.1021/bi200065g |Biochemistry 2011, 50, 2603–2610
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